CRNX - Company ID 0001658247
The table below shows Crinetics Pharmaceuticals, Inc.'s income statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $7.70M | $1.04M | $4.01M | $4.74M | $1.08M | $71.00K |
| Cost of revenue | $1.08M | $0.00 | $0.00 | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $332.06M | $240.16M | $168.53M | $130.22M | $84.25M | $57.00M |
| SG&A |
Crinetics Pharmaceuticals, Inc. reported annual revenue of $7.70M for fiscal year 2025. That is up 640.7% from $1.04M in fiscal 2024. Over the 10 fiscal years shown, annual revenue grew from $589.00K (FY 2016) to $7.70M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $191.33M |
| $99.74M |
| $58.09M |
| $42.39M |
| $24.52M |
| $18.03M |
| Operating income | -$516.77M | -$338.85M | -$222.61M | -$167.88M | -$107.70M | -$74.95M |
| Income tax | $180.00K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | -$465.30M | -$298.40M | -$214.50M | -$163.90M | -$107.60M | -$73.81M |
| EPS (diluted) | -$4.95 | -$3.69 | -$3.69 | -$3.15 | -$2.80 | -$2.42 |